Health Condition 1: L80- Vitiligo
Conditions
Interventions
Intervention1: Fractional CO2 laser–assisted topical tofacitinib (2 percent ointment) combined with 308 nm excimer laser therapy: CO2 laser: DEEP FX mode, 17.5–22.5 J/cm2, 10 percent density, 300 Hz,
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1. Phototherapy naïve adults aged 18–50 years with clinically diagnosed acral vitiligo (affecting hands and/or feet). 2. Stable vitiligo for at least 6 months prior to enrolment, defined by no new lesions or expansion of existing lesions. 3. Vitiligo Disease Activity (VIDA) score of 0–1, indicating stable or minimally active disease. 4. Symmetric or comparable bilateral acral lesions suitable for intraindividual comparison 5. Willingness to comply with study procedures and avoid other vitiligo treatments during the trial.
Exclusion criteria
Exclusion criteria: 1. Active or progressive vitiligo (VIDA score greater than 1). 2. History of hypersensitivity to tofacitinib, laser therapy, or excimer light. 3. Concomitant skin conditions (e.g., psoriasis, eczema) that could interfere with assessments. 4. Systemic immunosuppressive therapy within 4 weeks or topical treatments (including JAK inhibitor) within 4 weeks prior to enrolment. 5. Comorbidities such as active infection, malignancy, or severe hepatic/renal impairment. 6. Pregnancy, lactation, or inadequate contraception in women of childbearing potential
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of target acral vitiligo lesions achieving 50 percent or more repigmentation at week 24, assessed by standardized digital planimetry with blinded evaluation.Timepoint: After 24 Week | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of lesions with 75 percent and 90 percent or more repigmentation, mean percentage improvement in TL VESplus score, time to onset of 10 percent repigmentation, physician and patient global assessment of repigmentation, durability of response at week 36 with maintenance of 50 percent repigmentation without 25 percent loss, and incidence of adverse events, pain scores, and local reactions.Timepoint: After 24 Week | — |
Countries
India
Contacts
Public ContactDr Madura C
CUTIS Academy of Cutaneous Sciences
Outcome results
None listed